|
1983
|
|
Founding of Octapharma
|
|
1983
|
|
First commercial application of the SD technology for virus inactivation
|
|
1985
|
|
Octa V.I. low purity FVIII SD virus-inactivated
|
| 1987 |
|
SD virus-inactivated high-purity Factor VIII
|
| 1989 |
|
Acquisition of the Vienna plasma fractionation site
|
| 1991 |
|
World-first SD virus-inactivated, standardised Fresh Frozen Plasma (FFP) for transfusion
|
| 1995 |
|
World-first SD virus-inactivated liquid, ready-to-use immunoglobulin with a two-year shelf-life at room temperature
|
| 1999 |
|
Acquisition of the Lingolsheim plasma fractionation plant
|
| 2002 |
|
Acquisition of Biovitrum's Plasma Business in Sweden
|
| 2003 |
|
Acquisition of Probifasa SA - a Mexican plasma fractionation company
|
| 2003 |
|
Opening of Octapharma subsidiaries in USA and Spain
|
|
2004
|
|
octagam® approved in United States of America
|
2004
|
|
First virus-inactivated universally applicable transfusion plasma |
|
2004
|
|
Opening of Octapharma Australia and New Zealand
|
|
2005
|
|
First double virus-inactivated factor VIII / von Willebrand factor concentrate product
|
| 2006 |
|
Acquisition of five donor centers in Germany
|
| 2007 |
|
Opening of first Octapharma donor center in Germany
|
|
|
|
